To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Insperity reported a net loss of $20 million for Q3 2025, with diluted EPS at $(0.53), while adjusted EBITDA was $10 million and adjusted EPS was $(0.20) [5][7] - The company announced a multi-year contract extension with UnitedHealthcare, expected to provide significant cost reductions and improve financial outlook for 2026 [4][7] - Insperity's revenues for Q3 2025 increased by 4% year-over-year to $1.6 billion, driven by a 3% increase in revenue per worksite employee (WSEE) and a 1% increase in the average number of WSEEs [2][6] Financial Performance - Q3 2025 revenues reached $1.623 billion, up from $1.561 billion in Q3 2024, marking a 4% increase [7][22] - Gross profit decreased by 15% to $195 million in Q3 2025, primarily due to higher-than-expected benefits costs [3][22] - Operating expenses decreased by 4% to $220 million in Q3 2025 compared to $228 million in Q3 2024 [4][22] Year-to-Date Results - Year-to-date revenues increased by 4% to $5.1 billion, with an average of 309,327 WSEEs paid per month, also up by 1% [6][8] - Year-to-date net income was $26 million, with diluted EPS at $0.69 and adjusted EBITDA at $144 million [8][9] - The company returned $87 million to shareholders through share repurchases and cash dividends in the first nine months of 2025 [7][9] Strategic Developments - The rollout of HRScale, a strategic joint development offering with Workday, is expected to enhance Insperity's market position and drive future growth [2][4] - The new contract with UnitedHealthcare will reduce the pooling level for large claims to $500,000 starting January 1, 2026, which is anticipated to provide outstanding value for plan participants [4][7] Guidance and Outlook - Insperity provided updated guidance for 2025, projecting an average of 313,000 WSEEs paid in Q4 2025, with adjusted EPS expected to range from $(0.79) to $(0.16) [11][29] - The company anticipates a year-over-year decrease in adjusted EBITDA for Q4 2025, projecting a range of $(25) million to $9 million [11][29]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Insperity, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether Insperity has engaged in unlawful business practices that may have led to financial losses for investors [2]. Financial Performance - On August 1, 2025, Insperity reported adjusted earnings per share of $0.26, which was a 70% decline year-over-year and missed analyst estimates [6]. - The company attributed its poor performance to higher-than-expected benefits costs, including rising pharmacy expenses and an increase in large insurance claims [6]. - Following the announcement, Insperity's stock price dropped by $14.51, or 24.35%, closing at $45.07 per share on the same day [6]. Next Steps for Investors - Investors who purchased Insperity shares and suffered losses are encouraged to contact Bragar Eagel & Squire for more information regarding their legal rights and potential claims [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation across the United States [4].

Core Insights - The Insperity HR360 solution has demonstrated a 77% return on investment over three years for a composite organization, providing significant cost and time savings through strategic HR guidance and compliance support [3][4]. Financial Impact - The Forrester study quantified financial benefits leading to a 77% ROI over three years [3]. - Insperity's 2024 revenues are projected to be $6.6 billion, indicating strong financial performance [7]. Qualitative Benefits - The solution resulted in a 50% reduction in executive time spent on HR workflows, a 75% reduction in manager time spent on performance reviews, and an 80% reduction in onboarding time for new hires [6]. - There was a 90% reduction in HR-related noncompliance risk, enhancing overall organizational compliance [6]. - Clients reported improved talent acquisition and retention due to comprehensive employee benefits [6]. - The HR360 solution supports workforce development with training and compliance tools, leading to stronger teams [6]. - Employee satisfaction improved through reliable HR support and user-friendly self-service tools [6]. - The solution provides actionable guidance and best practices that help shape organizational culture [6]. Company Overview - Insperity, Inc. is a leading provider of human resources and business performance solutions, with a mission to help businesses succeed and communities prosper [7]. - The company has over 90 sales offices across the U.S. and is actively making a difference in thousands of businesses and communities [7].

Company Overview - Insperity, Inc. is a human resources and business solutions company that provides payroll, benefits, compliance, and talent management services to small and midsize businesses across the United States [3]. Allegations and Financial Impact - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Insperity due to allegations of providing potentially misleading business information to the investing public [1]. - On August 1, 2025, Insperity disclosed a 70% year-over-year decline in earnings per share for the second quarter of 2025, attributing this decline to rising pharmacy expenses, increased benefit costs, and large insurance claims [4]. - Following the earnings announcement, Insperity's stock price fell by $14.51 per share, or 24.35%, closing at $45.07 per share on August 1, 2025 [4]. - The company also revised down its full-year earnings guidance for 2025 [4].

Core Insights - Insperity, Inc. reported a significant decline in adjusted earnings per share for Q2 2025, with a figure of $0.26, which is a 70% decrease year-over-year, missing analyst expectations [3] - The company attributed this decline to higher-than-expected benefits costs, particularly due to rising pharmacy expenses and an increase in large insurance claims [3] - Following the earnings announcement, Insperity's stock price dropped by $14.51, or 24.35%, closing at $45.07 per share on August 1, 2025 [4] Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Insperity on behalf of its stockholders, focusing on possible violations of federal securities laws and other unlawful business practices [2] - The law firm encourages investors who have suffered losses to contact them for discussions regarding their legal rights [1][5] Company Background - Insperity, Inc. is publicly traded on the NYSE under the ticker NSP and is involved in providing human resources and business performance solutions [3] - The law firm Bragar Eagel & Squire, P.C. specializes in representing individual and institutional investors in complex litigation across various courts in the United States [6]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Insperity, Inc. and its officers or directors following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - On August 1, 2025, Insperity reported adjusted earnings per share of $0.26 for Q2 2025, which was a 70% decline year-over-year and below analyst expectations [3]. - The company attributed the poor performance to higher-than-expected benefits costs, particularly due to rising pharmacy expenses and an increase in large insurance claims [3]. - Following the announcement, Insperity's stock price fell by $14.51, or 24.35%, closing at $45.07 per share on the same day [4]. Legal Investigation - Pomerantz LLP is actively seeking claims from investors of Insperity regarding potential securities fraud or other unlawful practices [1]. - The firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [5].

Core Viewpoint - Insperity, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant decline in its financial performance and stock price [1][3]. Financial Performance - On August 1, 2025, Insperity reported adjusted earnings per share of $0.26 for Q2 2025, which was a 70% decline year-over-year and below analyst expectations [3]. - The company attributed its poor performance to higher-than-expected benefits costs, particularly due to rising pharmacy expenses and an increase in large insurance claims [3]. - Following the earnings announcement, Insperity's stock price dropped by $14.51, or 24.35%, closing at $45.07 per share [4]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Insperity investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - Insperity, Inc. is under investigation for potential securities fraud following a significant decline in its financial performance, which has led to a sharp drop in its stock price [1][2][3]. Financial Performance - Insperity reported adjusted earnings per share of $0.26 for Q2 2025, which was a 70% decline year-over-year and below analyst expectations [2]. - The company attributed its poor performance to higher-than-expected benefits costs, particularly due to rising pharmacy expenses and an increase in large insurance claims [2]. - Following the announcement of these results, Insperity's stock price fell by $14.51, or 24.35%, closing at $45.07 per share on August 1, 2025 [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Insperity investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - Insperity, Inc. is under investigation for possible securities fraud following disappointing financial results, which has led to a significant decline in its stock price [1][3][4]. Financial Performance - Insperity reported adjusted earnings per share of $0.26 for Q2 2025, which was a 70% decline compared to the same period in the previous year [3]. - The company attributed the poor performance to higher-than-expected benefits costs, including increased pharmacy expenses and a rise in large insurance claims [3]. - Following the earnings announcement, Insperity's stock price fell by $14.51, or approximately 24.35%, closing at $45.07 per share on August 1, 2025 [4]. Legal Actions - The Portnoy Law Firm has initiated an investigation into Insperity and may file a class action on behalf of investors who suffered losses [1]. - Investors are encouraged to contact the law firm for a complimentary case evaluation and to discuss their legal rights [2].